Ganga Pharmaceuticals (539680) H2 22/23 earnings summary

Executive summary

• FY23 total income reached Rs. 288.45 lakh and profit after tax Rs. 3.93 lakh; Ayurvedic medicines manufacturing, marketing and distribution remained the core business.

• Statutory auditors issued an unmodified opinion; internal financial controls were considered adequate and operating effectively.

Financial highlights

• Revenue from operations was Rs. 258.63 lakh in FY23 vs Rs. 248.90 lakh in FY22; total income was Rs. 288.45 lakh vs Rs. 274.76 lakh.

• Profit before tax was Rs. 5.31 lakh vs Rs. 5.12 lakh; profit after tax was Rs. 3.93 lakh vs Rs. 3.79 lakh.

• Total expenses were Rs. 283.14 lakh vs Rs. 269.64 lakh; tax expense was Rs. 1.38 lakh vs Rs. 1.33 lakh.

Outlook and guidance

• Long-term strategy centers on authentic Ayurveda, customer satisfaction, domestic market opportunities, expanded distribution and products addressing unmet health needs.

• New formulations have undergone human clinical trials; plans include product and technology development and investment in distribution networks.

• Management cited AYUSH cluster development, rural healthcare initiatives and 100% FDI permission in the AYUSH sector as supportive policy developments.